ArticlePloS one2025
Evaluation of the utility of cardiac biomarkers for risk stratification in patients with lower extremity artery disease: A retrospective study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Critical limb threatening ischemia (CLTI) is associated with a one-year mortality rate of up to 25% making prompt diagnosis essentially. This study aims to investigate if cardiac biomarkers may serve as an effective tool for risk stratification in patients with lower extremity artery disease (LEAD). For this cross-sectional retrospective analysis, 21712 patients with LEAD were screened for eligibility from 2004 to 2020. Out of these patients, 367 were included and subdivided into those with CLTI and those without CLTI. Cardiac biomarkers, including N-terminal prohormone of brain natriuretic peptide (NT-proBNP), troponin, NT-proBNP/troponin ratio, creatin kinase myocardial band (CK-MB) and myoglobin, were retrospectively analyzed. Fifty-nine patients had CLTI (16.1%) with higher rates of NT-proBNP, NT-proBNP/troponin ratio, CK-MB and myoglobin (all p < 0.05) compared to non-CLTI patients. In univariate analysis, NT-proBNP, NT-proBNP/troponin ratio, CK-MB, myoglobin, age, C-reactive protein and non-insulin dependent diabetes mellitus (NIDDM) were associated with CLTI (all p < 0.05). In multivariate analysis, age and NIDDM remained significant predictors (all p < 0.05) while cardiac biomarkers were not independently associated with CLTI. Troponin, NT-proBNP and myoglobin were associated with mortality in univariate analysis (all p < 0.05). In multivariate analysis, troponin only remains to be associated with mortality (p = 0.001). Selected cardiac biomarkers failed to demonstrate statistically significant differentiation between CLTI and non-CLTI patients with LEAD, while troponin may be potentially associated with mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.